CA2871996A1 - Proteine de tri 1 associee a un recepteur couple a une proteine g en tant que biomarqueur du cancer - Google Patents

Proteine de tri 1 associee a un recepteur couple a une proteine g en tant que biomarqueur du cancer Download PDF

Info

Publication number
CA2871996A1
CA2871996A1 CA2871996A CA2871996A CA2871996A1 CA 2871996 A1 CA2871996 A1 CA 2871996A1 CA 2871996 A CA2871996 A CA 2871996A CA 2871996 A CA2871996 A CA 2871996A CA 2871996 A1 CA2871996 A1 CA 2871996A1
Authority
CA
Canada
Prior art keywords
gasp
cancer
subject
expression level
early stage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2871996A
Other languages
English (en)
Inventor
Frank N. Chang
George P. Tuszynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/464,174 external-priority patent/US8420333B2/en
Priority claimed from US13/800,741 external-priority patent/US8980269B2/en
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Publication of CA2871996A1 publication Critical patent/CA2871996A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2871996A 2012-05-04 2013-05-03 Proteine de tri 1 associee a un recepteur couple a une proteine g en tant que biomarqueur du cancer Abandoned CA2871996A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/464,174 2012-05-04
US13/464,174 US8420333B2 (en) 2009-07-14 2012-05-04 G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker
US13/800,741 US8980269B2 (en) 2009-07-14 2013-03-13 G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker
US13/800,741 2013-03-13
PCT/US2013/039430 WO2013166364A1 (fr) 2012-05-04 2013-05-03 Protéine de tri 1 associée à un récepteur couplé à une protéine g en tant que biomarqueur du cancer

Publications (1)

Publication Number Publication Date
CA2871996A1 true CA2871996A1 (fr) 2013-11-07

Family

ID=49514902

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2871996A Abandoned CA2871996A1 (fr) 2012-05-04 2013-05-03 Proteine de tri 1 associee a un recepteur couple a une proteine g en tant que biomarqueur du cancer

Country Status (5)

Country Link
EP (1) EP2845008A4 (fr)
AU (1) AU2013256109A1 (fr)
CA (1) CA2871996A1 (fr)
TW (1) TW201400498A (fr)
WO (1) WO2013166364A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104330570B (zh) * 2014-10-11 2016-03-16 中国科学院微生物研究所 人热休克蛋白gp96在制备筛查肝病的产品中的应用
WO2019217705A1 (fr) * 2018-05-11 2019-11-14 Proplex Technologies, LLC Protéines de liaison et lymphocytes t de récepteur antigénique chimérique ciblant des granules de gasp-1 et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964365B2 (en) * 2005-11-08 2011-06-21 The United States of Americam as represented by the Secretary, Department of Health and Human Services Methods for diagnosing and monitoring the progression of cancer
EP2263085A4 (fr) * 2008-03-05 2011-07-06 Singulex Inc Procédés et compositions pour une détection hautement sensible de molécules
EP2454280A2 (fr) * 2009-07-14 2012-05-23 Temple University Of The Commonwealth System Of Higher Education Marqueurs dans le sérum associés à des stades précoces et à d'autres stades d'un cancer du sein

Also Published As

Publication number Publication date
AU2013256109A1 (en) 2014-12-04
TW201400498A (zh) 2014-01-01
EP2845008A4 (fr) 2016-03-23
EP2845008A1 (fr) 2015-03-11
WO2013166364A1 (fr) 2013-11-07

Similar Documents

Publication Publication Date Title
Ye et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine
Schiffer et al. Prediction of muscle-invasive bladder cancer using urinary proteomics
CA2767914C (fr) Marqueurs de cancer endometrial
Kim et al. Multi‐miRNA panel of tumor‐derived extracellular vesicles as promising diagnostic biomarkers of early‐stage breast cancer
US9182415B2 (en) Use of IMP3 as a prognostic marker for cancer
US8980269B2 (en) G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker
KR20160045547A (ko) 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법
US20140274794A1 (en) Methods and Compositions for Diagnosis of Ovarian Cancer
Chang et al. Expression and clinical significance of NEDD9 in lung tissues
US8420333B2 (en) G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker
US10338076B2 (en) Methods and compositions for the diagnosis of ovarian cancer
JP2022058635A (ja) 大腸癌の検出及び処置方法
Jung et al. The HCCR oncoprotein as a biomarker for human breast cancer
US20070264643A1 (en) Compositions and Methods Relating to CNS Lymphoma
Cheng et al. Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer
CA2871996A1 (fr) Proteine de tri 1 associee a un recepteur couple a une proteine g en tant que biomarqueur du cancer
WO2004085676A1 (fr) Methode de detection in vitro du carcinome a cellules transitionnelles de la vessie
JP2022153482A (ja) 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ
WO2017219093A1 (fr) Procédés de criblage
US20090233295A1 (en) Trim59 directed diagnostics for neoplastic disease
US20090068670A1 (en) Stratifin directed diagnostics for neoplastic disease
US20190016821A1 (en) Stabilized peptide fragments from protocadherin fat1 as cancer biomarkers
WO2013096852A1 (fr) Biomarqueurs du cancer
KR101456683B1 (ko) 폐암 진단용 마커
CN109971854B (zh) 用于开发宫颈疾病的诊疗产品的靶分子

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180417

FZDE Discontinued

Effective date: 20200831